Expectations are on the rise for Life360 following second quarter results
Brokers raise target prices for Avita Medical following second quarter results amidst anticipation of exciting prospects in the outlook period
Tim Boreham outlines the rise and fall of IDT Australia, and its potential revival in the cannabis and psychedelic drug market
Analysts raise target prices for SiteMinder after management brings forward the time frame for being free cash flow positive
Oncology radiology leader Telix Pharmaceuticals is taking on the US, Tim Boreham reports
Analysts remain positive on Syrah Resources despite current weak market conditions for graphite
Tim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics
Skin repair specialist PolyNovo remains confident in its firm growth path ahead
New research highlights Retail Food Group’s resilience to a consumer downturn and several capital-light growth opportunities
Brokers explain a negative share price reaction to Johns Lyng’s upgraded FY23 guidance